Inhibikase Therapeutics (IKT) CFO gets 986,319 options grant detail

Rhea-AI Filing Summary

Inhibikase Therapeutics reported an insider equity award for its Chief Financial Officer, David McIntyre. He received a stock option grant covering 986,319 shares of common stock at an exercise price of $2.01 per share on January 5, 2026. The option was granted at a cost of $0 on the grant date, so no shares were bought or sold in this transaction.

The option vests and becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and is scheduled to expire on January 5, 2036. Following this grant, McIntyre beneficially owns derivative securities representing 986,319 option rights held directly.

Insights

Equity compensation analyst

Routine CFO stock option grant with long-term monthly vesting.

The company awarded Chief Financial Officer David McIntyre a stock option on January 5, 2026 for 986,319 shares of common stock at an exercise price of $2.01 per share. The grant was recorded at a price of $0 for this Form 4, which means it represents an award rather than an immediate purchase or sale of shares.

The option vests in 36 equal monthly installments beginning on January 5, 2026, creating a three-year vesting period that depends on McIntyre’s continued employment. The option expires on January 5, 2036, giving a long window in which it can be exercised if it becomes economically attractive. After this grant, he directly holds derivative securities representing 986,319 option rights.

This looks like a standard executive equity incentive designed to align the CFO’s interests with long-term company performance, without indicating any sale of existing shares or change in control.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McIntyre David

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.01	01/05/2026		A		986,319		(1)	01/05/2036	Common Stock	986,319	$0	986,319	D

Explanation of Responses:

1. The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

	/s/ Mark Iwicki, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who received the stock option grant reported in Inhibikase Therapeutics (IKT) Form 4?

The grant was made to David McIntyre, the Chief Financial Officer of Inhibikase Therapeutics.

How many shares are covered by the CFO stock option in IKT's Form 4?

The stock option gives the CFO the right to purchase 986,319 shares of Inhibikase Therapeutics common stock.

What is the exercise price and expiration date of the Inhibikase CFO stock option?

The option has an exercise price of $2.01 per share and an expiration date of January 5, 2036.

When does the Inhibikase (IKT) CFO option begin vesting and over what period?

The option begins vesting on January 5, 2026 and vests in 36 equal monthly installments, subject to continued employment.

Did the Inhibikase CFO buy or sell shares in this Form 4 filing?

No shares were bought or sold; the Form 4 reports a stock option grant with a recorded transaction price of $0 and an exercise price of $2.01 per share.

How many derivative securities does the Inhibikase CFO own after this Form 4 transaction?

After the reported option grant, the CFO beneficially owns 986,319 derivative securities (stock option rights) directly.